stockrow
Friday 6 November 2026
Export GMED’s income statement to Excel — free account
Globus Medical, Inc.
GMED Healthcare Medical Devices
Globus Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 16.7% from fiscal 2024.
- Revenue
- −0.69%
- EPS
- +19.3%
- Free cash flow
- +10.1%
Quarter to September 2026, against a year earlier
72.24
9.20
−11.30%
Follow GMED
Alert me
Globus Medical, Inc. (GMED) Total debt
Globus Medical, Inc.'s total debt at the end of fiscal 2024 was $443.4M, up 6.22% from $417.4M in fiscal 2023. Over the past ten years it has ranged from $2.0M (fiscal 2019) to $443.4M (fiscal 2024) — the current reading is the highest in ten years. Globus Medical, Inc. ranks 29th of 147 Medical Devices companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2024 | $443.4M | 6.22% |
| FY2023 | $417.4M | 8,248.00% |
| FY2021 | $5.0M | 0.00% |
| FY2020 | $5.0M | 150.00% |
| FY2019 | $2.0M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Dec 2024 | $443.4M | 1.42% |
| Sep 2024 | $437.1M | 1.55% |
| Jun 2024 | $430.5M | 1.52% |
| Mar 2024 | $424.0M | 1.59% |
| 11 more quarters | Free account |
Against its own ten years
Low $2.0M
High $443.4M
Ten-year median
$5.0M
Current reading's percentile
100
Total debt against peers
| Company | Total debt |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $3.2B |
| BRKR Bruker Corporation compare | $1.7B |
| BIO.B Bio-Rad Laboratories, Inc. compare | $1.2B |
| BIO Bio-Rad Laboratories, Inc. compare | $1.2B |
| PODD Insulet Corporation compare | $962.1M |
| GMED Globus Medical, Inc. | $443.4M |
| TXG 10x Genomics compare | $98.0M |
| GKOS Glaukos Corporation compare | $66.9M |
| PEN Penumbra, Inc. compare | $19.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on GMED
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement